Quick Answer
Cyclerion Therapeutics, Inc. reported Research And Development Expense of $959.0 thousand for the year ending 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +235.3% in Research And Development Expense from 2024 to 2025.
- This data is from Cyclerion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $21.51 million | Q2 2018: $22.25 million | Q3 2018: $21.50 million | Q1 2019: $26.40 million | Q2 2019: $25.76 million | Q3 2019: $22.30 million | Q1 2020: $16.83 million | Q2 2020: $13.79 million | Q3 2020: $13.70 million | Q1 2021: $8.09 million | Q2 2021: $12.05 million | Q3 2021: $7.03 million | Q1 2022: $9.74 million | Q2 2022: $10.22 million | Q3 2022: $1.41 million | Q1 2023: $572.0 thousand | Q2 2023: $339.0 thousand | Q3 2023: $580.0 thousand | Q1 2024: $44.0 thousand | Q2 2024: $105.0 thousand | Q3 2024: $81.0 thousand | Q1 2025: $36.0 thousand | Q2 2025: $56.0 thousand | Q3 2025: $348.0 thousand.
- Over the full 8 years of available data (2018 to 2025), Cyclerion Therapeutics, Inc.'s Research And Development Expense has declined by 98.9%.
- Historical annual values: Fiscal year 2025: $959.0 thousand | Fiscal year 2024: $286.0 thousand | Fiscal year 2023: $1.52 million | Fiscal year 2022: $5.98 million | Fiscal year 2021: $37.64 million | Fiscal year 2020: $56.41 million | Fiscal year 2019: $95.14 million | Fiscal year 2018: $87.72 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: